IDEAYA Biosciences, Inc.
IDYANASDAQHealthcare● Active
$31.48
+$3.19(+11.28%)
Market Cap$2.8B
P/E Ratio—
52W High$39.28
52W Low$20.455
IDEAYA Biosciences, Inc. (IDYA) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · IDYA · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.22B | $0.01B | $0.02B | $0.05B | $0.03B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.21B | $0.00B | $0.02B | $0.05B | $0.03B |
| Gross Margin %(computed) | 97.90% | 45.23% | 82.86% | 95.87% | 93.83% |
| Operating Expenses | |||||
| R&D Expenses | $0.31B | $0.29B | $0.13B | $0.09B | $0.06B |
| G&A Expenses | $0.06B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.37B | $0.33B | $0.15B | $0.11B | $0.08B |
| Operating Income | ($0.16B) | ($0.33B) | ($0.13B) | ($0.06B) | ($0.05B) |
| Operating Margin %(computed) | -72.84% | — | -574.85% | -122.72% | -179.91% |
| Interest Income | $0.05B | $0.05B | $0.02B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.11B) | ($0.27B) | ($0.11B) | ($0.06B) | ($0.05B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.11B) | ($0.27B) | ($0.11B) | ($0.06B) | ($0.05B) |
| Net Margin %(computed) | -51.99% | — | -483.05% | -115.17% | -178.10% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.28 | $-3.36 | $-1.96 | $-1.42 | $-1.41 |
| Wtd Avg Shares | 0.09B | 0.08B | 0.06B | 0.04B | 0.04B |
| EBITDA | ($0.15B) | ($0.27B) | ($0.11B) | ($0.06B) | ($0.05B) |
| EBITDA Margin %(computed) | -70.74% | — | -465.91% | -111.04% | -171.92% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more IDEAYA Biosciences, Inc. data
About IDEAYA Biosciences, Inc. (IDYA) Income Statement
IDEAYA Biosciences, Inc. (IDYA) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, IDYA reported revenue of $0.22B, gross profit of $0.21B (gross margin 97.90%), and net income of ($0.11B) — a net profit margin of -51.99%.
Frequently asked questions
IDYA · 4 questionsIDEAYA Biosciences, Inc. (IDYA) reported revenue of $0.22B for 2025, up 3024.4% year-over-year.
IDYA revenueIDYA salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08